Defining outcomes for beta cell replacement therapy: a work in progress

Lorenzo Piemonti, Eelco J P de Koning, Thierry Berney, Jon S Odorico, James F Markmann, Peter G Stock, Michael R Rickels

Research output: Contribution to journal/periodicalArticleScientificpeer-review

11 Citations (Scopus)


Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.

Original languageEnglish
Pages (from-to)1273-1276
Number of pages4
Issue number6
Publication statusPublished - Jun 2018


  • Blood Glucose/analysis
  • C-Peptide/analysis
  • Europe
  • Glycated Hemoglobin A/analysis
  • Guidelines as Topic
  • Humans
  • Hypoglycemia/diagnosis
  • International Cooperation
  • Islets of Langerhans Transplantation/methods
  • Pancreas Transplantation/methods
  • Patient Satisfaction
  • Societies, Medical
  • Treatment Outcome


Dive into the research topics of 'Defining outcomes for beta cell replacement therapy: a work in progress'. Together they form a unique fingerprint.

Cite this